Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

IQV
IQVIA Holdings Inc.
stock NYSE

At Close
May 8, 2025 3:59:59 PM EDT
153.26USD-0.026%(-0.04)2,667,928
0.00Bid   0.00Ask   0.00Spread
Pre-market
May 6, 2025 9:27:30 AM EDT
150.02USD-2.140%(-3.28)0
After-hours
May 8, 2025 4:00:30 PM EDT
153.29USD+0.007%(+0.01)62,324
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 26, 2022
05:01PM EST  Sheila A. Stamps Joins IQVIA Board of Directors   Business Wire
Jan 24, 2022
05:00PM EST  Leslie Wims Morris Joins IQVIA Board of Directors   Business Wire
Dec 20, 2021
09:38AM EST  Where IQVIA Holdings Stands With Analysts   Benzinga
08:31AM EST  Mizuho Maintains Buy on IQVIA Holdings, Raises Price Target to $300   Benzinga
Dec 9, 2021
08:00AM EST  Global Medicine Spending to Reach $1.8 Trillion in 2026, Including Spending on COVID-19 Vaccines, According to Study by the IQVIA Institute for Human Data Science   Business Wire
Dec 6, 2021
07:00AM EST  ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic   GlobeNewswire Inc
Dec 2, 2021
08:00AM EST  IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Services Unit   Business Wire
Dec 1, 2021
08:00AM EST  IQVIA Recognized as a Leader in BPO Solutions for Pharmaceutical Sales and Marketing   Business Wire
Nov 19, 2021
10:38AM EST  IQVIA Launches New Grants/Funding Management Module for Its Orchestrated Customer Engagement Platform   Business Wire
Nov 18, 2021
07:06AM EST  Mizuho Maintains Buy on IQVIA Holdings, Raises Price Target to $290   Benzinga
06:41AM EST  Piper Sandler Maintains Neutral on IQVIA Holdings, Raises Price Target to $261   Benzinga
Nov 17, 2021
12:07PM EST  What 8 Analyst Ratings Have To Say About IQVIA Holdings   Benzinga
10:19AM EST  UBS Maintains Buy on IQVIA Holdings, Raises Price Target to $310   Benzinga
08:39AM EST  Jefferies Maintains Buy on IQVIA Holdings, Raises Price Target to $309   Benzinga
06:56AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
05:49AM EST  Keybanc Maintains Overweight on IQVIA Holdings, Raises Price Target to $290   Benzinga
Oct 27, 2021
12:23PM EDT  Where IQVIA Holdings Stands With Analysts   Benzinga
09:53AM EDT  Deutsche Bank Maintains Buy on IQVIA Holdings, Raises Price Target to $282   Benzinga
Oct 25, 2021
02:44PM EDT  Where IQVIA Holdings Stands With Analysts   Benzinga
10:17AM EDT  Barclays Maintains Overweight on IQVIA Holdings, Raises Price Target to $287   Benzinga
Oct 22, 2021
12:34PM EDT  Where IQVIA Holdings Stands With Analysts   Benzinga
09:48AM EDT  Morgan Stanley Maintains Overweight on IQVIA Holdings, Raises Price Target to $290   Benzinga
Oct 21, 2021
12:12PM EDT  IQVIA Holdings: Q3 Earnings Insights   Benzinga
12:11PM EDT  IQVIA Holdings Raises FY21 EPS Guidance From $8.70-$8.90 To $8.85-$8.95 Vs. $8.83 Est., Sales From $13.55B-$13.70B To $13.78B-$13.85B Vs. $13.68B Est.   Benzinga
12:11PM EDT  IQVIA Holdings Sees Q4 Sales $3.54B-$3.61B Vs. $3.48B Est.   Benzinga
12:11PM EDT  IQVIA Holdings Q3 EPS $2.17 Beats $2.12 Estimate, Sales $3.39B Beat $3.35B Estimate   Benzinga
12:11PM EDT  Earnings Scheduled For October 21, 2021   Benzinga
07:59AM EDT  Following strong third-quarter results and expressing confidence to sustain the momentum to the next year, QVIA Holdings (IQV) on Thursday raised its full-year guidance, better than the consensus estimates.   RTTNews
07:14AM EDT  IQVIA Holdings Inc. (IQV) revealed a profit for its third quarter that increased from the same period last year.   RTTNews
07:06AM EDT  IQVIA Holdings Q3 GAAP EPS $1.34 Vs. $0.52 Last Year   RTTNews
07:00AM EDT  IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance   Business Wire
Oct 20, 2021
10:16AM EDT  IQVIA Holdings's Earnings Outlook   Benzinga
Oct 15, 2021
12:13PM EDT  Expert Ratings For IQVIA Holdings   Benzinga
09:30AM EDT  UPDATE: KeyBanc On IQVIA Price Target Raise: Firm Updates Targeted Annual Revenue Growth From 6-9% To 8-11% With Opportunity To Expand Into Lab Services For Precision Medicines; Highlights Recent Acquisition Of Biomarker Detection Business In Europe   Benzinga
07:29AM EDT  10 Biggest Price Target Changes For Friday   Benzinga
04:33AM EDT  Keybanc Maintains Overweight on IQVIA Holdings, Raises Price Target to $270   Benzinga
Oct 12, 2021
08:00AM EDT  IQVIA to Announce Third-Quarter 2021 Results on October 21, 2021   Business Wire
Oct 7, 2021
11:00AM EDT  IQVIA to Host Financial Analyst and Investor Conference on November 16, 2021   Business Wire
Oct 6, 2021
08:00AM EDT  IQVIA Announces Opening of New Q2 Solutions Innovation Laboratories in North Carolina, Creating New Jobs and Expanded Capabilities   Business Wire
Sep 30, 2021
08:00AM EDT  Polpharma Selects IQVIA's Orchestrated Customer Engagement Platform to Improve Salesforce Productivity   Business Wire
Sep 14, 2021
07:50AM EDT  The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout   Benzinga
Sep 13, 2021
04:16PM EDT  IQVIA And NRx Pharmaceuticals Collaborate On Potential Medical Support For Novel COVID-19 Treatment   Benzinga
Sep 10, 2021
07:36PM EDT  Where IQVIA Holdings Stands With Analysts   Benzinga
07:35PM EDT  Argus Research Maintains Buy on IQVIA Holdings, Raises Price Target to $290   Benzinga
Sep 8, 2021
09:32AM EDT  IQVIA (IQV) said that it has collaborated with HealthCore Inc., real world research organization in the United States, to advance real world evidence (RWE) studies with increased quality and efficiency.   RTTNews
08:06AM EDT  IQVIA Collaborates With HealthCore To 'Advance Clinical Research Using Real-World Data'   Benzinga
08:04AM EDT  IQVIA Collaborates With HealthCore To Advance Clinical Research Using Real-World Data   RTTNews
Sep 2, 2021
04:15PM EDT  IQVIA CFO, Ron Bruehlman, to Speak at the Baird 2021 Global Healthcare Conference on September 14, 2021   Business Wire
Sep 1, 2021
08:04AM EDT  IQVIA Launches New A.I.-Powered MI Contact Center For Life Sciences   RTTNews
Jul 29, 2021
12:02PM EDT  What 13 Analyst Ratings Have To Say About IQVIA Holdings   Benzinga
Jul 28, 2021
10:25AM EDT  Deutsche Bank Maintains Buy on IQVIA Holdings, Raises Price Target to $250   Benzinga
09:16AM EDT  Piper Sandler Maintains Neutral on IQVIA Holdings, Raises Price Target to $235   Benzinga
08:41AM EDT  Morgan Stanley Maintains Overweight on IQVIA Holdings, Raises Price Target to $280   Benzinga
Jul 27, 2021
11:13AM EDT  IQVIA Raises FY21 Adj. EPS Guidance From $8.50-$8.75 To $8.70-$8.90 To $8.69 Est., Raises Sales Guidance From $13.2B-$13.5B To $13.55B-$13.7B vs $13.44B Est.   Benzinga
11:13AM EDT  IQVIA Holdings Q2 Adj. EPS $2.13 Beats $2.07 Estimate, Sales $3.44B Beat $3.27B Estimate   Benzinga
11:13AM EDT  Recap: IQVIA Q2 Earnings   Benzinga
04:03AM EDT  Earnings Scheduled For July 27, 2021   Benzinga
Jul 22, 2021
08:00AM EDT  Consumer Health Apps and Digital Health Tools Proliferate, Improving Quality and Health Outcomes for Patients, Says New Report from IQVIA Institute   Business Wire
Jul 20, 2021
08:22AM EDT  Credit Suisse Maintains Outperform on IQVIA Holdings, Raises Price Target to $265   Benzinga
Jul 13, 2021
02:00PM EDT  Where IQVIA Holdings Stands With Analysts   Benzinga
08:57AM EDT  Barclays Maintains Overweight on IQVIA Holdings, Raises Price Target to $285   Benzinga
Jun 24, 2021
04:16PM EDT  IQVIA Launches the Clinical Data Analytics Suite to Enable Smarter, Faster Clinical Trials   Benzinga
04:15PM EDT  IQVIA Launches the Clinical Data Analytics Suite (CDAS) to Enable Smarter, Faster Clinical Trials   Business Wire
Jun 14, 2021
08:08AM EDT  IQVIA Holdings Expands its Laboratory in Scotland   Benzinga
08:00AM EDT  Q Solutions Announces Significant Expansion of Laboratory Operations in Scotland, UK   Business Wire
Jun 8, 2021
08:13AM EDT  IQVIA Holdings' Q2 Solutions Says Collaborates With Tasso   Benzinga
08:08AM EDT  Q2 Solutions Announces Transformative Collaboration With Tasso Inc.   RTTNews
08:00AM EDT  Q2 Solutions and Tasso Collaborate to Provide Unique Solutions for Patients to Accelerate Adoption of Decentralized Clinical Trials   Business Wire
Jun 3, 2021
04:30PM EDT  Global Oncology Innovation Continues Despite Pandemic; Global R&D Pipeline Reached 3,500 New Drugs in 2020, up 75% from 2015, Says New Report from the IQVIA Institute for Human Data Science   Business Wire
09:22AM EDT  nView Health Announces Multi-year License Agreement With IQVIA   Benzinga
May 24, 2021
07:36AM EDT  Genetic testing and precision medicine company Myriad Genetics, Inc. (MYGN) announced Monday it has signed a definitive agreement to sell Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA Holdings, Inc. (IQV). The terms of the deal were not disclosed.   RTTNews
May 20, 2021
04:15PM EDT  IQVIA CFO, Ron Bruehlman, to Speak at the William Blair Growth Stock Conference on June 2, 2021   Business Wire
May 19, 2021
08:00AM EDT  Pharma R&D Activity Surges Even Without COVID-19, Says Report from the IQVIA Institute for Human Data Science   Business Wire
May 14, 2021
06:09AM EDT  Keybanc Maintains Overweight on IQVIA Holdings, Raises Price Target to $260   Benzinga
May 12, 2021
10:56AM EDT  CORRECTION: Canaccord Genuity Maintains Buy on IQVIA Holdings, Raises Price Target to $260 - The Correct Analyst Firm Is Argus   Benzinga
10:51AM EDT  Canaccord Genuity Maintains Buy on IQVIA Holdings, Raises Price Target to $260   Benzinga
08:13AM EDT  ProtoKinetix and IQVIA Partner to Support Development of AAGP Product in the Treatment of Ocular Conditions   Benzinga
May 11, 2021
09:07AM EDT  Veeva Systems: All Of Its Antitrust Claims Against IQVIA Still Stand And Are Proceeding To Trial   RTTNews
09:05AM EDT  Despite Disinformation Attempt, Antitrust Case Against IQVIA Moves Forward and   PR Newswire
May 10, 2021
09:25AM EDT  IQVIA (IQV) announced Monday that the U.S. District Court of New Jersey issued a favorable decision in its litigation with Veeva Systems, Inc. (VEEV). The Court ruled on IQVIA's motion for sanctions, finding Veeva engaged in massive destruction of evidence, engaged in a cover-up of its wrong-doing, and repeatedly lied about its actions.   RTTNews
08:22AM EDT  IQVIA Says Court Rules In Favor Of Co. Against Veeva   Benzinga
08:14AM EDT  IQVIA Says U.S. District Court Of New Jersey Issued Favorable Decision In Litigation With Veeva Systems   RTTNews
08:00AM EDT  U.S. District Court Issues Favorable Decision for IQVIA Against Veeva   Business Wire
May 3, 2021
08:09AM EDT  IQVIA To Collaborate With Corium To Support Launch Of AZSTARYS   RTTNews
08:00AM EDT  IQVIA's Orchestrated Customer Engagement (OCE) Solution Chosen to Support the Commercial Launch of Novel ADHD Drug   Business Wire
Apr 29, 2021
08:00AM EDT  Global Medicine Spending to Reach $1.6 Trillion in 2025 Excluding Spending on COVID-19 Vaccines, According to IQVIA Institute for Human Data Science Study   Business Wire
Apr 28, 2021
08:23AM EDT  IQVIA Announces Connected Intelligence   Benzinga
Apr 26, 2021
09:30AM EDT  Barclays Maintains Overweight on IQVIA Holdings, Raises Price Target to $260   Benzinga
09:22AM EDT  Truist Securities Maintains Buy on IQVIA Holdings, Raises Price Target to $260   Benzinga
08:21AM EDT  Morgan Stanley Maintains Overweight on IQVIA Holdings, Raises Price Target to $260   Benzinga
Apr 23, 2021
10:46AM EDT  Deutsche Bank Maintains Buy on IQVIA Holdings, Raises Price Target to $244   Benzinga
Apr 22, 2021
02:23PM EDT  Thursday, North Carolina-based technological solution provider to the life science industry, IQVIA Holdings Inc. (IQV) were up by 4.03% or $8.84 per share, at $227.84 per share after a positive result in the first quarter. The company managed to beat Street view and improved their guidance for the year.   RTTNews
12:21PM EDT  Earnings Scheduled For April 22, 2021   Benzinga
07:14AM EDT  IQVIA Raises FY21 Adj. EPS Guidance From $7.89-$8.20 To $8.50-$8.75 vs $8.04 Est., Raises Sales Guidance From $12.55B-$12.9B To $13.2B-$13.5B vs $12.83B Est.   Benzinga
07:13AM EDT  IQVIA Holdings Inc. (IQV) revealed earnings for its first quarter that climbed from last year.   RTTNews
07:13AM EDT  IQVIA Holdings Q1 Adj. EPS $2.18 Beats $1.85 Estimate, Sales $3.41B Beat $3.18B Estimate   Benzinga
07:05AM EDT  IQVIA Holdings Q1 GAAP EPS $1.09 Vs. $0.42 Last Year   RTTNews
07:00AM EDT  IQVIA Reports First-Quarter Results; Raises Full-Year 2021 Guidance   Business Wire
04:01AM EDT  Earnings Scheduled For April 22, 2021   Benzinga
Apr 21, 2021
10:43AM EDT  Earnings Outlook For IQVIA Holdings   Benzinga
Apr 16, 2021
10:08AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021   Benzinga
08:40AM EDT  Stephens & Co. Upgrades IQVIA Holdings to Overweight, Raises Price Target to $250   Benzinga
Apr 9, 2021
10:38AM EDT  Mizuho Maintains Buy on IQVIA Holdings, Raises Price Target to $218   Benzinga
Apr 6, 2021
01:00PM EDT  IQVIA to Announce First-Quarter 2021 Results on April 22, 2021   Business Wire
07:37AM EDT  A Look Into IQVIA's Debt   Benzinga
07:33AM EDT  Moleculin Biotech Announces Engagement Of IQVIA Biotech To Manage Potential Clinical Trials Of WP1122 For COVID-19   RTTNews
07:31AM EDT  Moleculin Engages IQVIA To Manage Potential COVID-19 Clinical Trial   Benzinga
Apr 1, 2021
09:37AM EDT  Quest Diagnostics Offloads Interest in Q2 Solutions JV To IQVIA   Benzinga
07:38AM EDT  IQVIA Holdings Inc. (IQV) announced the acquisition of the 40 percent minority share of Q2 Solutions from Quest Diagnostics (DGX), for $760 million, resulting in 100 percent ownership by IQVIA.   RTTNews
07:09AM EDT  IQVIA Raises FY21 Adj. EPS Guidance From $7.77-$8.08 To $7.89-$8.20 Vs. $7.98 Est.   Benzinga
07:08AM EDT  IQVIA Acquires Remaining 40% Interest in Q2 Solutions from Quest Diagnostics For $760M   Benzinga
07:04AM EDT  IQVIA Acquires Remaining 40% Minority Share Of Q2 Solutions From Quest Diagnostics For $760 Mln   RTTNews
07:04AM EDT  Quest Diagnostics Sells Ownership Interest in Q Solutions to IQVIA   PR Newswire
07:00AM EDT  IQVIA Acquires Remaining Interest in Q2 Solutions from Quest Diagnostics; Raises Full Year 2021 Adjusted Diluted EPS Guidance   Business Wire
Mar 9, 2021
08:00AM EST  IQVIA Virtual Trial Solutions Used in More than 60 Trials   Business Wire
Mar 8, 2021
10:04AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 8, 2021   Benzinga
08:48AM EST  IQVIA Collaborates With Janssen R&D On Investigational COVID-19 Vaccine Trials   RTTNews
08:46AM EST  IQVIA Collaborating with Janssen Research & Development on Their Investigational COVID-19 Vaccine Trials   Business Wire
08:02AM EST  IQVIA Says Since Sept. Has Been Collaborating With Janssen On Phase 3 COVID-19 Vaccine Trial, Says 'The studies leverage IQVIA's suite of decentralized trial solutions'; Financial Details Not Disclosed   Benzinga
05:01AM EST  KeyBanc Upgrades IQVIA Holdings to Overweight, Announces $218 Price Target   Benzinga
Mar 3, 2021
10:02AM EST  Benzinga's Top Ratings Upgrades, Downgrades For March 3, 2021   Benzinga
06:37AM EST  Barclays Initiates Coverage On IQVIA Holdings with Overweight Rating, Announces Price Target of $220   Benzinga
Mar 2, 2021
04:15PM EST  IQVIA to Participate in the Barclays Global Healthcare Conference on March 09, 2021   Business Wire
Feb 19, 2021
02:54PM EST  BBC StoryWorks/Paid-For Salesforce Blog Post 'How Virtual Clinical Trials Are Speeding The Path To Another Vaccine' Highlights How 'IQVIA has been helping pharmaceutical giants perform clinical trials...'; IQVIA Shares Unaffected   Benzinga
Feb 17, 2021
04:29PM EST  IQVIA Reports Pricing Of Offering Of Senior Notes   RTTNews
04:27PM EST  IQVIA Announces Pricing of Offering of Senior Notes   Business Wire
Feb 16, 2021
03:41AM EST  IQVIA To Raise EUR 1.45 Bln In Gross Proceeds Through Offering Of Senior Notes Due 2026 And Senior Notes Due 2029   RTTNews
03:26AM EST  IQVIA Announces Offering of Senior Notes   Business Wire
Feb 11, 2021
12:07PM EST  Wells Fargo Maintains Overweight on IQVIA Holdings, Raises Price Target to $230   Benzinga
11:21AM EST  Mizuho Maintains Buy on IQVIA Holdings, Raises Price Target to $210   Benzinga
08:50AM EST  Morgan Stanley Maintains Overweight on IQVIA Holdings, Raises Price Target to $220   Benzinga
08:00AM EST  IQVIA's Orchestrated Customer Engagement (OCE) Solution Selected by 140 Life Sciences Companies in Nearly 90 Countries   Business Wire
Feb 10, 2021
07:23AM EST  IQVIA Holdings: Q4 Earnings Insights   Benzinga
07:22AM EST  While reporting financial results for the fourth quarter on Wednesday, life sciences services company IQVIA Holdings Inc. (IQV) raised its adjusted earnings and revenue guidance for the full-year 2021 and provided financial outlook for the first quarter.   RTTNews
07:15AM EST  IQVIA Holdings Raises FY21 EPS Guidance From $7.65-$7.95 To $7.77-$8.08 Vs. $7.85 Est., Sales $12.3B-$12.6B To $12.55B-$12.90B Vs. $12.51B Est.   Benzinga
07:13AM EST  IQVIA Holdings Raises FY21 Guidance   Benzinga
07:13AM EST  IQVIA Holdings Q4 EPS $2.11 Beats $2.00 Estimate, Sales $3.30B Beat $3.14B Estimate   Benzinga
07:06AM EST  IQVIA Holdings Q4 Revenue $3.298 Bln Up 13.9% From Last Year   RTTNews
07:00AM EST  IQVIA Reports Fourth-Quarter and Full-Year 2020 Results Raises Full-Year 2021 Guidance   Business Wire
03:43AM EST  Earnings Scheduled For February 10, 2021   Benzinga
Feb 4, 2021
08:04AM EST  IQVIA Recognized as Leading eCOA/ePRO Provider in Latest 2020 ISR eCOA/ePRO Market Report   Business Wire
Feb 1, 2021
08:00AM EST  IQVIA Named to FORTUNE's 2021 List of "World's Most Admired Companies"   Business Wire
Jan 26, 2021
04:15PM EST  IQVIA to Announce Fourth-Quarter and Full-Year 2020 Results on February 10, 2021   Business Wire
Jan 5, 2021
08:04AM EST  Laboratoires Tha Selects IQVIA OCE And OneKey To Accelerate Global Digital Transformation   RTTNews
08:00AM EST  Laboratoires Tha Selects IQVIA OCE and OneKey to Accelerate Its Global Digital Transformation   Business Wire
Jan 2, 2021
01:49PM EST  Notable Insider Buys Of The Past Week: Danimer Scientific, Cheniere Energy Partners And More   Benzinga
Dec 21, 2020
07:35AM EST  Q2 Solutions Announces Partnership With Adaptive Biotechnologies   RTTNews
07:30AM EST  Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ(r) Assay, the Leading Quantitative Large-Scale Immunosequencing Solution   Business Wire
Dec 17, 2020
08:00AM EST  Prescription Opioid Use in the U.S. has Declined by 60% from 2011 Peak, According to New Report from the IQVIA(tm) Institute for Human Data Science   Business Wire
Dec 16, 2020
08:22AM EST  IQVIA Holdings Inc. (IQV), a provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, said Wednesday it will collaborate with pharmaceutical company Servier to reinvent the company's R&D clinical development processes.   RTTNews
08:04AM EST  IQVIA Announces Collaboration With Servier To Reinvent R&D Clinical Development Processes   RTTNews
08:00AM EST  IQVIA and Servier Collaborate to Reinvent Clinical Development   Business Wire
Dec 7, 2020
08:00AM EST  IQVIA Supports Collaborative Forum of Top Pharma Leaders to Advance the Use and Acceptance of Real World Evidence   Business Wire
Nov 2, 2020
08:09AM EST  Zentiva Leverages IQVIA's OCE Platform Across 12 Major Markets   RTTNews
08:00AM EST  IQVIA's Orchestrated Customer Engagement Platform Selected by Zentiva to Accelerate Digital Capabilities   Business Wire
Oct 21, 2020
07:56AM EDT  Morgan Stanley Maintains Overweight on IQVIA Holdings, Raises Price Target to $195   Benzinga
Oct 20, 2020
07:31AM EDT  IQVIA Holdings Inc. (IQV) reported earnings for its third quarter that rose from the same period last year.   RTTNews
07:16AM EDT  IQVIA Holdings: Q3 Earnings Insights   Benzinga
07:09AM EDT  IQVIA Q3 GAAP EPS $0.52; Adj EPS $1.63   RTTNews
07:04AM EDT  IQVIA Sees FY21 Adj. EPS $7.65-$7.95 vs $7.57 Est., Sales $12.3B-$12.6B vs $12.24B Est.   Benzinga
07:04AM EDT  IQVIA Reports Third-Quarter 2020 Results, Raises Full-Year 2020 Guidance and Provides 2021 Outlook   Business Wire
07:02AM EDT  IQVIA To Resume Buyback Program   Benzinga
07:02AM EDT  IQVIA Holdings Q3 Adj. EPS $1.63 Beats $1.52 Estimate, Sales $2.79B Beat $2.75B Estimate   Benzinga
04:01AM EDT  Earnings Scheduled For October 20, 2020   Benzinga
Oct 19, 2020
10:15AM EDT  A Preview Of IQVIA Holdings's Earnings   Benzinga
Oct 12, 2020
08:00AM EDT  IQVIA Joins FDA to Advance COVID-19 Understanding at Community Level through COVID Active Research Experience (CARE) Project   Business Wire
Oct 7, 2020
04:15PM EDT  IQVIA to Announce Third-Quarter Results on October 20, 2020   Business Wire
Oct 6, 2020
08:00AM EDT  IQVIA Institute for Human Data Science Study: Biosimilars Reach Inflection Point - On Track to Reduce Drug Costs by $100 Bn Over Next Five Years   Business Wire
Sep 14, 2020
08:10AM EDT  IQVIA's eCOA Solution Receives 2020 Fierce Innovation Award   Business Wire
Aug 31, 2020
08:58AM EDT  IQVIA's RIM Smart Honored as Gold Stevie(r) Award Winner in 2020 American Business Awards(r)   Business Wire
Aug 8, 2020
04:03PM EDT  Notable Insider Buys at Allovir, Xerox And Many More   Benzinga
Aug 5, 2020
08:00AM EDT  IQVIA's Nancy Dreyer and Deepa Desai Honored with 2020 PharmaVOICE Awards   Business Wire
Aug 4, 2020
08:00AM EDT  Drug Prices Have Become More Affordable to Most Patients, says U.S. Medicine Spending Study from the IQVIA Institute for Human Data Science   Business Wire
Jul 29, 2020
08:00AM EDT  IQVIA Launches OCE Optimizer to Help Intelligently Plan HCP Engagements and Maximize Commercial Effectiveness   Business Wire
Jul 28, 2020
11:22PM EDT  Earnings Scheduled For July 22, 2020   Benzinga
Jul 23, 2020
08:51AM EDT  10 Biggest Price Target Changes For Thursday   Benzinga
08:37AM EDT  Morgan Stanley Maintains Overweight on IQVIA Holdings, Raises Price Target to $182   Benzinga
08:00AM EDT  IQVIA Human Data Science Research Collaborative Initiative Waives Data Access Fees for Academic Researchers   Business Wire
07:14AM EDT  Mizuho Maintains Buy on IQVIA Holdings, Raises Price Target to $180   Benzinga
Jul 22, 2020
10:18AM EDT  A Look Into IQVIA's Price Over Earnings   Benzinga
07:58AM EDT  IQVIA Holdings: Q2 Earnings Insights   Benzinga
07:25AM EDT  IQVIA Holdings Inc. (IQV) said, for full year 2020, the company now projects adjusted earnings per share in a range of $6.10 - $6.30, revised from prior guidance range of $5.75 - $6.10. Revenue is now anticipated in the range of $11.00 billion - $11.10 billion, updated from prior guidance range of $10.60 billion - $10.93 billion.   RTTNews
07:05AM EDT  IQVIA Q2 Loss Per Share $0.12; Adj EPS $1.18   RTTNews
07:05AM EDT  IQVIA Raises FY20 Adj. EPS Guidance From $5.75-$6.10 To $6.10-$6.30 vs $5.87 Est., Raises Sales Guidance From $10.6B-$10.925B To $11B-$11.1B vs $10.74B Est.   Benzinga
07:03AM EDT  IQVIA Holdings Q2 Adj. EPS $1.18 Beats $1.06 Estimate, Sales $2.52B Beat $2.41B Estimate   Benzinga
07:00AM EDT  IQVIA Reports Second-Quarter 2020 Results and Raises Full-Year 2020 Guidance   Business Wire
04:11AM EDT  Earnings Scheduled For July 22, 2020   Benzinga
Jul 21, 2020
10:53PM EDT  Biogen Inc. (BIIB) said that it has appointed Michael McDonnell as Executive Vice President and Chief Financial Officer, effective August 15, 2020.   RTTNews
07:42PM EDT  IQVIA Appoints Ron Bruehlman As EVP And Interim CFO   RTTNews
06:00PM EDT  IQVIA Appoints Ron Bruehlman Executive Vice President and interim Chief Financial Officer   Business Wire
06:00PM EDT  Biogen Names Michael McDonnell as Executive Vice President and   GlobeNewswire Inc
Jul 20, 2020
08:06AM EDT  IQVIA, JDRF Partner To Improve Understanding Of Type 1 Diabetes Using Real World Data   RTTNews
08:01AM EDT  IQVIA and JDRF Collaborate to Improve Understanding of Type 1 Diabetes Using Real World Data   Business Wire
Jul 14, 2020
08:13AM EDT  IQVIA (IQV) has collaborated with AstraZeneca (AZN.L, AZN) to accelerate development of a potential new vaccine for COVID-19. The collaboration will drive faster delivery of clinical studies in the U.S. of AstraZeneca's potential COVID-19 vaccine, AZD1222. The joint initiative is part of the U.S. government's Operation Warp Speed project.   RTTNews
08:11AM EDT  IQVIA And AstraZeneca Team-Up To Support Development Of Potential COVID-19 Vaccine   Benzinga
08:04AM EDT  IQVIA Announces Collaboration With AstraZeneca To Accelerate Development Of Potential New Vaccine For COVID-19   RTTNews
08:00AM EDT  IQVIA and AstraZeneca Team-up to Support Development of Potential COVID-19 Vaccine   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC